Kornimate/medical-research-clean huggingface dataset:
an rct to evaluate the effect of a new skin care regimen on sbf in those with podoconiosis

Conditions: Non-filarial Elephantiasis

Summary: an rct (n=193) in two podoconiosis clinics in ethiopia to evaluate the effectiveness of a research based skin management regimen compared to the current regimen. the experimental group added 2% glycerine to the current skin care regimen and used 1 litre of water in the water soak compared to the 6 litres used in the current regimen.

background. podoconiosis (non-filarial elephantiasis) affects some of the poorest people in 20 countries in the world. in ethiopia least 3 million people are affected with 17 million at risk. irritant minerals (smectite, mica and quartz) from volcanic soil and pathogens enter skin breaches in the feet causing inflammation, lymphoedema and hyperkeratosis. podoconiosis is preventable and treatable but is not curable. current treatment consists of educating those with disease on its causes, prevention and treatment. treatment taught in the action on podoconiosis (apa) clinics consists of a daily hygiene regimen of washing the feet/legs with soap, soaking the feet and legs in water with sodium hypochlorite (naoci) (0.0125%) added as a disinfectant, air drying and the application of a thin layer of petrolatum jelly. whitfields ointment (benzoic acid and salicylic acid) is applied to any fungal infections. wearing shoes is encouraged but this does not offer complete protection against the alkaline soil. although the current treatment skin care regimen is effective there is no robust evidence on optimal skin care regimens to improve skin barrier function in this disease. objective. to evaluate the effectiveness of a new, low-cost, evidence-based skin care intervention to improve sbf in the lower limbs of those with podoconiosis. method. a randomized control trial (rct) was conducted over 3 months in two apa clinics (n=193). intervention was 2% glycerine (v/v) added to a reduced amount of soaking water (1 litre versus 6 litres). the control group received the current skin care regimen. the primary outcome measure was skin barrier function (sbf). this was determined by measures of trans-epidermal water loss (tewl) and stratum corneum hydration (sch) at four specific sites on the lower limbs.

Eligibility criteria:
inclusion criteria: * patients in ethiopia with a diagnosis of podoconiosis. that is those living above 1000 feet sea level with high rainfall, above 1,00mm annually with foot or lower leg oedema which had started in the feet, with sensation present in the feet and no hand involvement. the diagnosis was determined by the nurses at the outreach clinics. * patients who were able to understand instructions and give informed consent as determined by the nurses at the outreach clinics. * patients over 18 years of age. exclusion criteria: * patients not diagnosed with podoconiosis as determined by nurses at the outreach clinics. * patients who were unable to understand instructions or give informed consent as determined by nurses at the outreach clinics. * patients under 18 years of age.

Keywords: podoconiosis glycerine rct sbf tewl sc hydration
evaluation of 1440nm laser assisted selective photothermolysis for treatment of axillary hyperhidrosis

Conditions: Hyperhidrosis

Summary: the purpose of this study is to evaluate the safety and efficacy of the nd:yag 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.


Eligibility criteria:
inclusion criteria: * a healthy non-smoking male or female between 18-55 years of age * understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment * understand and accept the obligation and is logistically able to present for all scheduled follow-up visits * clinically diagnosed for primary hyperhidrosis of the axilla. * a self-assessed hyperhidrosis disease severity scale (hdss) score of three (3) or four (4) exclusion criteria: * clinical diagnosis of secondary hyperhidrosis * uncontrolled systemic disease or infection * concurrent use of any hyperhidrosis treatments other than over the counter antiperspirants or deodorants * receipt of botox® or dysport® within the past six months * patients who refuse to stop using over the counter antiperspirants 24 hours prior to the day of surgery and each of the follow-up visits at 3 months and 6 months that minors starch iodine tests may be performed. * patients using or having used within 7 days of baseline visit: cholinomimetic agents, anticholinergic agents, prescription antiperspirants, any herbal medicine treatments or any other treatments for hyperhidrosis except over the counter antiperspirant or planning to use such agents during the course of the study. * any previous liposuction/liposculpture or any type of surgery for hyperhidrosis; or any other types of treatments for hyperhidrosis in the area to be treated in the past 6 months * has any other medical condition, that, in the investigator's opinion would interfere with the subject's participation in the study * is susceptible to light induced seizures or history of seizures * has a history of keloid formation * significant cardiovascular disease * bleeding disorders * anti-platelet and anticoagulant medication * sensitivity to lidocaine or epinephrine * pregnancy or planned pregnancy * existing neuromuscular disorders (myasthenia gravis, eaton-lambert syndrome, amyotrophic lateral sclerosis) * electronic implants * subjects requiring supplemental oxygen * has therapies or medications which may interfere with the treatment (including medications causing photosensitivity * allergic to doxycycline
zynrelef vs exparel: the battle of postoperative pain control after robotic sleeve gastrectomy

Conditions: Post Operative Pain

Summary: the purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (zynrelef) vs injectable liposomal bupivacaine (exparel), two extended local anesthesia strategies currently approved by fda and on the market for post-surgical pain control. the investigators plan on randomizing study participants to either exparel or zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. the investigators will measure the outcome of two drugs, zynrelief, and exparel on postoperative pain score -using the nrs pin score up to 72 hours after surgery. the total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the excel sheet. the cost of the drug will be calculated for internal use for hospital purpose only.


Eligibility criteria:
inclusion criteria: 1. age range: 18-65 years old 2. scheduled or being scheduled to undergo robotic sleeve gastrectomy by dr. goyal. 3. is able to provide written informed consent. 4. is able to adhere to the study visit schedule and complete all study assessments. exclusion criteria: 1. positive urine drug screen prior to surgery 2. history of substance abuse in the past year-by self report 3. patient with ongoing daily narcotic use at the time of surgery-by self report 4. inability to understand informed consent or read english/spanish 5. pregnant or lactating patients 6. prisoners 7. patients with renal or hepatic failure 8. bupivacaine use within 96 hours of operation 9. patient intolerant of opiates, nonsteroidal anti-inflammatory drug s, acetaminophen, or zynrelef and exparel. subjects in all cohorts must not have any contraindications to any of the protocol-specified drugs 10. patient with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients

Keywords: robotic surgery sleeve gastrectomy zynrelef exparel
early outcomes of radical debridement versus no debridement under different surgical procedures

Conditions: Spinal Tuberculosis

Summary: whether radical debridement is necessary for the treatment of thoracic and lumbar tuberculosis is still questionable. the objective of this prospective randomized study was to compare the outcomes of radical debridement versus no debridement under different surgical procedures for the treatment of thoracic and lumbar tuberculosis.

seventy-four thoracic and lumbar tuberculosis patients with a neurological function of grade d and e underwent surgeries from january 2009 to january 2014. all patients were divided into group a and group b by taking the drawing of lots. in group a, radical debridement, bone graft and instrumentation were performed. in group b, isolated posterior instrumentation without debridement were performed in all cases and drainage of iliopsoas abscess via laparoscopy in 2 cases. the operative time, blood loss, visual analogue score (vas), erythrocyte sedimentation rate (esr), kyphotic angle, frankel grading, fusion rate and complications were evaluated.

Eligibility criteria:
inclusion criteria: 1. frankel grading was grade d and e 2. severe back pain 3. abscess combined with high pressure symptoms 4. larger sequestrum formation or sinus 5. significant spinal instability. exclusion criteria: 1. frankel grading was grade a,b and c 2. conservative treatment
app-based emotion recognition training improve asd social function

Conditions: Autism Spectrum Disorder High-Functioning

Summary: the main aim of the study is to investigate whether app-based emotional recognition training improve social function in autistic children.

50 asd children age ranged from 4-10 years old will be randomly allocated to either app-based emotional recognition training or memory training groups for 2 months. before and after training, some assessements were measured including autism diagnostic observation schedule-2, childhood autism rating scale, wechsler intelligence scale and psychoeducational profile-3. some other questionnaires are also collected including social responsibility scale-2,repetitive behavior scale-revised,caregiver strains questionnaire，social communication questionnaire，social anxiety scale for children，adaptive behavior assessment schedule. four eye-tracking tasks as follows: (1) dynamic geometrical paired with dynamic child dancing; (2) static neutral and emotional faces; (3) a dynamic gaze-following task; (4) social interaction behaviors paired with the toys alone; (5) spinning actions conducted via children paired with objects.

Eligibility criteria:
inclusion criteria: clinical diagnosis of autism spectrum disorder and follow these criteria: (1) age range: 4-10 years old, gender not limited;(2) ethnicity: han nationality;(3) autism diagnostic observation schedule-second edition (ados-2) comparison score greater than or equal to 5 points (le et al., 2022);(4) considering that only high-functioning autism individuals can successfully complete the eye-tracking tasks, children with a wechsler score greater than or equal to 60 points are selected; exclusion criteria: (1) no neurological complications, such as epilepsy, cerebral palsy, fragile x syndrome, etc.;(2) no prior medical interventions, such as taking antipsychotic drugs, receiving transcranial magnetic stimulation, acupuncture, etc.;(3) no abnormal imaging diagnosis or any brain injury.
mild to moderate erectile dysfunction study

Conditions: Impotence

Summary: safety/efficacy of 100-mg viagra at 8 hours post dose in men with mild to moderate erectile dysfunction


Eligibility criteria:
inclusion criteria: * men 18-70 years of age * documented clinical diagnosis of erectile dysfunction of at least 3 months duration. exclusion criteria: * subjects with penile implants * subjects with a known history of retinitis pigmentosa. * subjects, due to the requirement of 100 mg dosage, who are receiving concomitant treatment with the potent cyp3a4 inhibitor ritonavir.
an investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke.

Conditions: Stroke, Ischemic

Summary: uncertainty remains regarding the impact of enteric-coated (ec) aspirin as it relates to the reduction of cv risk. we hypothesize that ec formulation based on the previous report may blunt aspirin response as evidenced by reduced thromboxane a2 (txa 2) levels in diabetic patients.


Eligibility criteria:
inclusion criteria: 1. newly diagnosed ischemic stroke who are just about to start aspirin. 2. no prior history of cardiovascular morbidity (including ischemic heart disease, chronic kidney disease, peripheral vascular disease) 3-18- 75 years. 4-patients with ischemic stroke who underwent reperfusion intervention (catheter-directed thrombolysis and/or thrombectomy) regardless of the time of presentation (i.e within or outside the therapeutic window as the managing stroke deem fit. exclusion criteria: 1. concomitant antiplatelet therapy (irrespective of the duration of the treatment). 2. patients on any prostaglandins related medications (non-steroidal anti-inflammatory drugs, misoprostol, and other ant secretory drugs among others). 3. any salicylate-containing supplements. 4. patients on the ng tube will be excluded from the study
intra-arterial chemotherapy for retinoblastoma

Conditions: Retinoblastoma

Summary: children with retinoblastoma who may benefit from intra-arterial chemotherapy will receive up to 3 doses of melphalan and will be assessed for feasibility, toxicity, and response.


Eligibility criteria:
inclusion criteria: * patients diagnosed with retinoblastoma \>4 months of age16 * patients whose other treatment options would require systemic chemotherapy, radiotherapy, or enucleation * patient or parent/legal guardian must sign a written informed consent * one of a, b, or c: * patients who have bilateral cog stage b, c, d, or e retinoblastoma (refer to appendix a) who have undergone systemic chemotherapy without resolution (meaning either has not had cr or has progressed despite systemic chemotherapy) and would have the following treatment options remaining: * iac * enucleation of one eye * local radiation * patients with non-germline retinoblastoma with unilateral disease who have cog a, b, c, or d tumors (refer to appendix a). * other patients may be considered on a case by case basis after discussion with pediatric ophthalmology, hematology/oncology, and interventional neuroradiology. exclusion criteria: * opaque or hazy media which precluded visualization of the fundus. * new or recurrent retinoblastoma that can be controlled with other conservative measures such as cryotherapy, thermotherapy, or plaque radiotherapy. * unilateral cog group e retinoblastoma (refer to appendix a) with very poor visual prognosis as defined by pediatric ophthalmologist. * patients who would benefit from systemic chemotherapy. * patients with clinical or radiological evidence suggestive of retinoblastoma invasion of the optic nerve, choroid, sclera, orbit or metastatic sites. * currently receiving any other investigational agents. * a history of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan or other agents used in the study. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. * pregnant and/or breastfeeding. participants of childbearing potential must have a negative pregnancy test within 14 days of study entry. * patients with hiv are eligible unless their cd4+ t-cell counts are \< 350 cells/mcl or they have a history of aids-defining opportunistic infection within the 12 months prior to registration. concurrent treatment with effective art according to dhhs treatment guidelines is recommended.
portal vein pulsatility index to assess fluid intolerance

Conditions: Venous Congestion

Summary: this study uses the portal vein pulsatility index (pvpi) to assess fluid intolerance amongst fluid responders.

this prospective observational study aims to use the portal vein pulsatility index (pvpi) to assess fluid intolerance in fluid responders. the investigators will enroll mechanically ventilated postoperative adult patients within 6 hours of icu admission after cardiac surgery. patients will undergo a passive leg raising (plr) test and left ventricular outflow tract (lvot) recording using transthoracic echocardiography. the main objective is to predict fluid intolerance after a fluid challenge of 7 ml/kg ringer lactate over 10 minutes in initially tolerant fluid responders.

Eligibility criteria:
inclusion criteria: * informed consent. * mechanically ventilated patients within 6 hours after icu admission following surgery who are considered for fluid administration to optimize haemodynamics. * sinus rhythm. exclusion criteria: * a condition known to interfere with portal vein flow assessment or interpretation (liver cirrhosis or chronic hepatic disease, suprahepatic or portal vein thrombosis). * any mechanical circulatory support. * cardiac transplant. * poor transthoracic echocardiographic window.

Keywords: congestion portal vein pulsatility ultrasound fluid responsiveness fluid tolerance
the sense of small and inhibition in obesity

Conditions: Obesity

Summary: the aim of this research is to verify whether inhibitory control ability is different between a group of individuals with obesity and a group of individuals with normal weight in the presence of olfactory stimuli, different for valence, edibility (food versus no-food), and caloric density (high-calorie vs low-calorie content) of foods associated with odours.


Eligibility criteria:
inclusion criteria: * right-handed * diagnosis of obesity (i.e., the level of body mass index (bmi) higher or equal to 30). exclusion criteria: * concurrent neurological, neurodevelopmental (e.g., autism), motor, somatosensory and/or psychiatric disorders.

Keywords: obesity smell food cognitive inhibition
"vrtierone" as a method supporting the post-stroke rehabilitation

Conditions: Stroke; Depression

Summary: thanks to using vr googles and the phenomenon of total immersion "vr tier one" allows to completely separate the patient from the hospital environment, provides an intense visual, auditory and kinesthetic stimulation. depending on the stage of therapy it can have a calming and mood-improving effect or, in another part of the game, it can motivate and cognitively activate the patient. the additional aim of the game is to help the patients regain their emotional balance, let them recognize their resources in order to bring them to power in the rehabilitation process and trigger the natural recovery mechanisms.

the goals of the project: 1. the evaluation of the influence of virtual therapeutic game on the mood and wellbeing of the patients undergoing post-stroke rehabilitation. 2. the evaluation of the influence of virtual therapeutic game on the acceptance of the illness and self-efficacy assessment of the patients undergoing post-stroke rehabilitation. 3. the evaluation of the influence of virtual therapeutic game on the effectiveness of post-stroke rehabilitation process in relation to locomotive function as well as basic and instrumental activities of daily living. 4. the analysis of possible side effects appearing while using virtual reality therapy.

Eligibility criteria:
inclusion criteria: * ischemic stroke * depression symptoms scored 10 and more in geriatric depression scale (gds-30) exclusion criteria: * cognitive functions (mmse\<24) * epilepsy, * vertigo, * aphasia and a serious loss of sight or hearing that makes it impossible to assess cognitive functions based on mmse, * presence at the time of the examination or in the medical data: mental retardation, disturbances of consciousness or other serious mental disorders, * patient's refusal at any stage of the research project

Keywords: stroke post-stroke rehabilitation virtual reality depression mental health
the efficacy and safety of tofacitinib in patients with glucocorticoid resistant icis-related myocarditis

Conditions: Glucocorticoid Resistant ICIs-related Myocarditis

Summary: the efficacy and safety of tofacitinib in patients with glucocorticoid resistant icis-related myocarditis: a single-arm, prospective, phase 2 trial


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. patients treated with ici immunotherapy (monotherapy or combination), including anti-pd1, anti-pdl1, anti-ctla4; and including any type of cancer (even those in which ici is not currently approved by regulatory) 3. definite, probable or possible ici-induced myocarditis according to the diagnostic criteria of the most recent expert consensus recommendations (e.g27, to be updated with any new recommendations to be published) 4. corticosteroid-resistant ici-myocarditis: corticosteroid-resistant ici-myocarditis is defined by the absence of decrease in troponin levels or the appearance/persistence of severity criteria despite receiving prednisone dose ≥0.5 mg/kg/day for ≥2 days. 5. signature of informed consent before any trial procedure from the patient or legal representative or the close relative 6. patients covered by social security regimen (excepting ame) 7. withhold of ici exclusion criteria: 1. untreated and/or uncontrolled bacterial, fungal, or viral infection pregnancy, breast-feeding or planning to become pregnant during the study period 2. for women of childbearing age, lack of effective contraception throughout the duration of participation in the study 3. being treated with tofacitinib within 3 months prior to inclusion known hypersensitivity to abatacept or belatacept 4. being treated with anti-thymoglobulin, or alemtuzumab within 6 weeks of the first scheduled dose of abatacept 5. patient participating to another interventional study (riph 1 only) people under legal protection measure (tutorship, curatorship or safeguard measures)
visceral pain from the upper urinary tract - a trial on the effect of morphine and oxycodone in patients undergoing pcnl

Conditions: Kidney Stones

Summary: the purpose of this study is to investigate the effect of oxynorm versus morphine after operation for kidney stone (pcnl). in addition the relationship between pain symptoms and referred sensory and trophic changes will be examined in the patients before and after the operation.finally a blood sample is analysed to investigate pharmaca-genetics.

primary outcome: the amount of opioid (morphine or oxynorm) used the first 4 hours postoperatively. secondary outcome: side effect to the opioids, pain score, pain threshold to electrical stimulation and pressure before and after operation, pharmacogenetics, size of referred pain area.

Eligibility criteria:
inclusion criteria: * age \> 18 * indication for pcnl exclusion criteria: * malignant disease in the upper urinary tract * allergy to morphine or oxycodone * use of opioids the last 48 hours before pcnl * pregnancy * nursing mothers * present jj-stent in the ureter * previous urinary stone disease on the opposite site

Keywords: pcnl oxycodone morphine visceral pain